Transdermal Oestradiol Patches Non-inferior to LHRH Agonists Regarding Metastasis-Free Survival in Patients with Locally Advanced Prostate Cancer By Ogkologos - April 16, 2026 196 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a phase III study in patients recruited through the PATCH and STAMPEDE-1 trial networks Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Relacorilant Annual Multicancer Early Detection Test Not Associated with a Lower Incidence Rate of Stage III or IV Cancer After Three Screening Rounds and 12... ESMO welcomes the adoption of European Parliament Report on Europe’s Beating Cancer Plan in the Committee on Public Health (SANT), calls for further EU... MOST POPULAR FDA Approves Mirdametinib for Adult and Paediatric Patients with NF1 Who... March 20, 2025 Medicare Open Enrollment Starts Tomorrow! October 14, 2021 New ESMO President 2029-2030 Elected June 3, 2026 Toddler Celebrates 11 Months Cancer-Free In Adorable Dance Video With Dad. October 17, 2019 Load more HOT NEWS Early-onset cancer: why are more young adults being diagnosed? New chemotherapy-free treatment for bowel cancer made available in Scotland Por qué no voy a “superar” los efectos a largo plazo... Targeting the Accomplice: A Potential Treatment Approach for Rhabdomyosarcoma
